ABX464-001
15 evidence topics · 3 sources
Objective
Location and study date
Study dates and status in the registry record
| Field | Registry entry |
|---|---|
| Recruitment status | “Completed” |
| Study start | “2014-03” |
| Primary completion (actual) | “2014-07” |
| Other study ID numbers | “ABX464-001” |
Study design
Open-label, single ascending dose design with sentinel dosing
Eligibility criteria
Treatment
Single oral dose of 50 to 200 mg after overnight fasting
Study outcomes
Rationale for using the percentage of participants with at least one adverse event as the primary endpoint
Registered primary and secondary outcomes
Safety assessments and pharmacokinetic analytes
“Safety assessments consisted of vital signs, electrocardiogram, physical examination, laboratory tests and urinalysis. Pharmacokinetic parameters were calculated for ABX464 and its main metabolite ABX-464- N -glucuronide (ABX464-NGlc).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry record
| Field | Registry entry |
|---|---|
| Enrollment (actual) | “24” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Pharmacokinetics of obefazimod and its N-glucuronide metabolite
“ABX464's Cmax was observed approximately 2 h after administration in all groups. ABX464 was rapidly and substantially metabolized into ABX464-NGlc. The Cmax of ABX464-NGlc was observed approximately 4 h post-dose and was about 160-fold higher than that of the parent with a much longer t1/2 (90-110 h). The ratio of metabolite to parent drug was consistent across the complete dose range.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Tolerability across the 50 to 200 mg doses
Description of the first-in-human results in the food-effect publication
Study limitations
Summary
ABX464-001 gave a single oral dose of 50, 100, 150, or 200 mg after overnight fasting to 24 healthy men, 6 per dose group. It had no placebo group and no repeated dosing, enrolled men only, and all doses were given fasted. The full article is closed access, and the abstract gives no numerical pharmacokinetic parameters by dose, no adverse event counts, and no dose-proportionality analysis beyond stating that the metabolite-to-parent ratio “was consistent across the complete dose range”. The registry record posts no results, and four of eight authors list Abivax as their affiliation.
Author affiliations in the abstract record
“Scherrer D(1), Rouzier R(2), Noel Barrett P(3), Steens JM(1), Gineste P(1), Murphy RL(4), Tazi J(5), Ehrlich HJ(1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“(1)ABIVAX, 5 Rue de la Baume, 75008 Paris, France.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote